Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

th chronic

lymphocytic leukemia is expected to be started in the United States by

Micromet's collaboration partner MedImmune. In addition, at the

conference of the American Society of Hematology (ASH) in December 2008,

Micromet anticipates that it will provide an update on the clinical

data of the ongoing clinical trials with MT103.

-- Micromet expects to initiate dosing of patients in a phase 1 clinical

trial of MT110 in patients with solid tumors in the first half of 2008.

-- Micromet is currently developing the study design for a clinical trial

to evaluate adecatumumab (MT201) in an adjuvant setting and plans to

initiate this clinical trial in the second half of 2008. In addition,

data of the ongoing phase 1b combination trial with docetaxel are

expected to be presented in the second half of 2008.

-- Micromet expects to initiate IND-enabling studies with MT203 as part of

its collaboration with Nycomed.

Conference Call and Audio Webcast Today, March 13, 2007, at 9:00am Eastern Time

To participate in this conference call, dial 800-561-2813 (U.S.) or 617-614-3529 (international), passcode: 29595857. The audio webcast can be accessed at: http://www.micromet-inc.com in the investor relations section of the website.

A replay of the call will be available from 11:00 am Eastern Time on March 13, 2008 (4:00 pm Central European Time) through Thursday, March 20, 2008. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 40638317.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are currently in clinical t
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... JOSE, California , January 15, 2014 ... cancer, today announced the appointment of Thomas C Reynolds MD, ... 20 years, development experience gained in the biotechnology industry, most ... "I am delighted to welcome Tom at this transformative time ...
(Date:1/15/2014)... January 15, 2014 More than 5 ... about 1 in 3 seniors will die with Alzheimer’s ... These jaw-dropping figures have shocked many Americans into looking ... help prevent these tragic age-related cognitive disorders. Jonathan Weisman, ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 2013 was ... Scottsdale’s Brain State Technologies®. They saw continued independent research ... Center who were awarded a $1 million grant from ... in “Brain and Behavior” a peer reviewed journal, Amy ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... of Angel Soft website Madison, Wis. Imagine, says ... that you actually want to watch it again and again. ... Soft toilet paper by international tissue and paper manufacturer Georgia-Pacific. ... asks him what he is doing," Ramsey told a crowd ...
... exceeded expectations, reaching $3.6 billion in 2002, according to a new ... 2005. , ,In 2002, the state ranked 20 th ... in academic R&D spending. , ,"You'd be hard-pressed to find ... few years," said David Ward, president of NorthStar Economics ...
... has announced the release of Centricity Physician Office ... for physicians that extends the functionality of Centricity Physician ... , , Centricity Physician Office Mobile ... and schedules and to capture charges from any location. ...
Cached Biology Technology:Consumer "engagement" stressed at e-Business seminar 2Consumer "engagement" stressed at e-Business seminar 3New report says Wisconsin R&D spending exceeding expectations 2
(Date:4/16/2014)... From far away, the top of a leaf looks ... exterior is actually made up of a patchwork of ... in how these cells individually take on their own ... Sampathkumar, and colleagues sought to pinpoint the shape-controlling factors ...
(Date:4/16/2014)... muscular atrophy (SBMA) is a rare inherited neuromuscular disorder characterized ... considered it to be essentially an affliction of primary motor ... that control muscle movement. , But in a new study ... Neuron , a team of scientists at the University of ...
(Date:4/16/2014)... director of the Physical Biosciences Division of Lawrence Berkeley ... recognized as a leading authority on the evolutionary design ... to systems and synthetic biology, has been named one ... Award by U.S. Energy Secretary Ernest Moniz. The E.O. ...
Breaking Biology News(10 mins):For cells, internal stress leads to unique shapes 2Mutant protein in muscle linked to neuromuscular disorder 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 3
... University of Wisconsin School of Medicine and Public Health ... taking part in a novel clinical trial investigating if ... of severe coronary artery disease. , The trial, just ... in the Autologous Cellular Therapy CD34-Chronic Myocardial Ischemia (ACT34-CMI) ...
... but also too much iron is bad for our ... where it can lead to organ failure and even ... Researchers from the Innsbruck Medical University, the University of ... now made a surprising discovery that may lead to ...
... play a pivotal role in the inception of Darwin’s theory ... their significance when he collected them during his voyage on ... predict the impact the vast amount of marine microbial DNA ... J. Craig Venter, Ph.D., and his team ?will have on ...
Cached Biology News:UW launches study testing adult stem cells for heart damage repair 2UW launches study testing adult stem cells for heart damage repair 3Putting an old drug to a new use 2Darwin's famous finches and Venter's marine microbes 2Darwin's famous finches and Venter's marine microbes 3Darwin's famous finches and Venter's marine microbes 4Darwin's famous finches and Venter's marine microbes 5
... Express Cloning Checker Kits provide two ... after transformation without time-consuming plasmid preparation. By ... I, all you need to do is ... bacteria directly from the transformation plates into ...
GLP-1 (HYB 147-12)...
... Immunogen KLH-conjugated, synthetic peptide ... (RRGPHRNPG-PGDDDGQRSRSSS) of mouse p19ARF. ... amino acids 62-75. Clone 5-C3-1. ... evaluated by immunoblot. ...
EDTA, tetrasodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99-101% (as is).Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemicals, Ul...
Biology Products: